Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist originally approved for the treatment of type 2 diabetes but now FDA approved for chronic weight management in overweight and obese individuals
It should only be considered after reviewing potential benefits, risks, side effects, costs, and the patients medical history
When you stop the medication, ghrelin levels surge back within days, and many patients report intense cravings and constant hunger within 1-2 weeks
Semaglutide can reduce hunger, but it does not automatically fix poor nutrition quality, low activity, alcohol excess, chronic stress, or hormonal issues that may be contributing to weight gain
Some medical protocols combine them to address both systemic recovery and localized repair